The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


The Journal of Immunology, 1943, 46: 163-175.
Copyright © 1943 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Henle, W.
Right arrow Articles by Stokes, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Henle, W.
Right arrow Articles by Stokes, J., Jr.

Demonstration of the Efficacy of Vaccination Against Influenza Type A by Experimental Infection of Human Beings

Werner Henle, Gertrude Henle and Joseph Stokes, Jr.

From the Department of Pediatrics, School of Medicine, University of Pennsylvania, and The Children's Hospital of Philadelphia

Abstract

The efficacy of allantoic fluid vaccines in the prevention of experimental human infection with the virus of influenza A has been studied. Of 28 control individuals, 10 came down with clinical influenza following inhalation of a recently isolated active virus. Only 1 case, which had not responded to vaccination, occurred among the 44 vaccinated persons, 27 of which had been immunized 4 months prior to the exposure.

There was good correlation between the pre-inhalation antibody level and the degree of protection in that most of the clinical cases occurred in the group with the lowest antibody titer as measured both by mouse protection and inhibition of red cell agglutination technic. Increase in the antibody level decreased the morbidity.

The clinical picture of the experimental disease confirmed the observation of earlier investigators. Since a number of individuals harbored pathogenic organisms in the upper respiratory tract, all clinical cases were treated with sulfonamides. No complications were encountered.

Subclinical infections were numerous, as shown by slight elevations of temperature, mostly on the second or fourth day after inhalation, leucopenia below 5000, or rises in antibodies 2 weeks following the exposure. These symptoms were independent of each other in that either one alone or any combination of the three could be found. Virus was re-isolated only from clinical cases.

Various questions concerning the subclinical infections are discussed.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1943 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1943 by The American Association of Immunologists, Inc. All rights reserved.